Oils4cure, a Madrid biotech, develops YCJ-01, a full-spectrum extract of Cannabis sativa with cannabidiol and THC in a 20 to 1 ratio, produced under GMP conditions, for refractory epilepsy in tuberous sclerosis complex, a genetic disease that causes tumours in the brain and other organs. It was selected in the EIC Accelerator's March 2023 cut-off and received an EU grant of €1.56 million for a €2.23 million project that ran from December 2023 to August 2026, according to CORDIS. The aim was to test YCJ-01's effect on seizures in a clinical trial; the company says the Spanish medicines agency fast-tracked it to Phase 3 on the basis of observational data.
The only public report, to November 2024, says contracts for the starting material and trial drug were signed, the drug was delivered to hospitals and "the first patient was enrolled", and that "first results" show fewer seizures and a good safety profile, according to the CORDIS reporting page. The SPECTRUM trial plans 84 patients aged 2 to 65, randomised to YCJ-01 or placebo for two months, followed by four months of open-label treatment, according to Oils4cure. It was registered on ClinicalTrials.gov in February 2026 and listed as recruiting, with an estimated primary completion in June 2026, according to ClinicalTrials.gov. No results have been published.
Company file
- Legal entity
- Oils4cure S.L., Madrid
- Share capital
- €12,380
- Revenue band
- Under €500,000 a year
- Lead drug
- YCJ-01, full-spectrum cannabis extract
- Second programme
- YCJ-02, leukodystrophies
- Suppliers named
- Cañamos Farmland, Medalchemy
- EIC funding
- Grant first
Where Oils4cure Stands Now
Oils4cure is a small company, with share capital of €12,380 and annual revenue under €500,000, according to Empresia. The trial registry lists one site, Hospital Ruber Internacional in Madrid. The company's recent news covers conference sponsorship and a scientific meeting on tuberous sclerosis in November 2025, but no trial update. The report says Spain's medicines agency allows compassionate use of YCJ-01 for patients who had fewer seizures during the trial.
"The first results of the drug's effects indicate it produces a reduction in the number of epileptic crises, as well as cognitive and behavioural improvements in the patients, coupled to a good safety profile."
Oils4cure, first periodic report to the EICThe Technology: The Whole Plant, Not One Molecule
Epidyolex, a cannabidiol-based medicine, is already approved for seizures in tuberous sclerosis, but Oils4cure says its side effects, price and efficacy leave room for improvement. YCJ-01 keeps many compounds of the plant, on the theory that they work together, and the company expects it to work at lower doses. That "entourage effect" has not been proven in controlled trials, which is what SPECTRUM is designed to test.
What the EIC Award Promised, and What the Record Shows
The award promised a clinical trial testing YCJ-01's efficacy against seizures. The trial was set up, supplied and started. At the halfway point only the first patient had been enrolled, and when the project ended the trial was still recruiting. The early efficacy claims in the report came from a trial still in progress, before its comparison with placebo was complete.
- GMP trial drug supplyDeliveredDelivered to hospitals.
- Phase 3 trial startDeliveredJune 2024.
- Trial completionNot doneStill recruiting.
- Patent protectionUnverifiedExpected end 2025.
The Money
The EU paid 70% of the project. The grant was several times the company's annual revenue. No private funding round has been announced, and taking a drug through approval after Phase 3 needs far more money than the company has disclosed.
What Cannot Be Checked
Questions for the EIC
How many patients SPECTRUM has enrolled, what the blinded results show, whether the European patent was granted, and how Oils4cure will fund a marketing application are not public.
Why Europe Should Care
Children with tuberous sclerosis whose seizures resist treatment risk impaired development, and their families have few options. A well-controlled trial of a full-spectrum cannabis medicine would give doctors real evidence in a field full of unproven products. The EIC paid for that trial to begin; its answer is not yet public.
What the award promised
A clinical trial showing whether YCJ-01 reduces seizures in tuberous sclerosis.
What the record shows
A Phase 3 trial started at one Madrid hospital, still recruiting at project end.
The Verdict
Trial under way, answer pending
Oils4cure started the trial the EIC funded but did not finish it within the project. Whether YCJ-01 works will only be known when the blinded results are published.
Oils4cure and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
